What Cannabis Rescheduling Means for Stock Prices in 2026

The potential rescheduling of cannabis from Schedule I to Schedule III has been the most significant catalyst for cannabis stock prices. Here we break down the financial impact and what investors should expect.

The most immediate benefit of rescheduling would be the elimination of Section 280E taxation. US cannabis companies currently face effective tax rates of 50-80% because they cannot deduct ordinary business expenses. Removing this burden could save the industry billions annually and dramatically improve profitability for multi-state operators.

Beyond tax relief, rescheduling could unlock institutional capital. Many funds, banks, and asset managers have policies preventing investment in Schedule I-related businesses. A reclassification to Schedule III would remove this barrier, potentially driving significant new capital into the sector.

However, investors should temper expectations. Rescheduling alone does not legalize recreational cannabis at the federal level, and the regulatory framework would still require state-by-state licensing. The timeline for implementation also remains uncertain, and legal challenges could delay the process further.

For portfolio positioning, consider diversified exposure through cannabis ETFs like MSOS for US operator exposure, while maintaining awareness that individual stock selection based on balance sheet strength and state footprint will determine who benefits most from reform.